Peter
Mason is the Chief Technology Officer of Ervaxx, Ltd., in London, UK
(2017-present). Prior to joining Ervaxx, Dr. Mason was the Executive
Director of the Infectious Diseases Group at Regeneron Pharmaceuticals,
Inc. in Tarrytown, NY (2014-2017). Despite his geographic distance from
Texas, Dr. Mason has continued to maintain his affiliation with UTMB
through the SIVS. In 2002, he joined the faculty at UTMB as a Professor
of Pathology and a Senior Scientist in the Sealy Center for Vaccine
Development (SCVD). His contributions to infectious disease research at
UTMB included his co-invention of a new method to produce flavivirus
vaccines (currently licensed to a pharmaceutical company and a
veterinary company) and new methods to study flavivirus pathogenesis
using single-cycle infectious particles.
Search PubMed for Dr. Mason's publications.